Three-dimensional structure micelles of heparin-poloxamer improve the therapeutic effect of 17β-estradiol on endometrial regeneration for intrauterine adhesions in a rat model

Abstract: Intrauterine adhesions (IUA) frequently occur after infectious or mechanical injury to the endometrium, which may lead to infertility and/or pregnancy complications. There are few effective treatments due to the complex function of endometrium and shortage of native materials. 17β-estradiol (E\textsubscript{2}) is commonly used as an ancillary treatment in IUA patients, but it is limited by its poor solubility in aqueous solutions and low concentrations at the injured sites. In this research, a mini-endometrial curette was used to injure the rat’s endometrium to form an IUA model. 17β-estradiol was encapsulated into the micelles of heparin-poloxamer and a thermosensitive hydrogel (E\textsubscript{2}-HP hydrogel) was formed. This sustained releasing system was applied to restore the structure and function of the injured uterus. E\textsubscript{2}-HP hydrogel was constructed and relevant characteristics including gelation temperature and micromorphology were evaluated. Sustained release of 17β-estradiol from HP hydrogel was performed both in vitro and in vivo. Ultrasonography measurement and pathologic characteristics on the IUA rats were performed to evaluate the therapeutic effect of E\textsubscript{2}-HP hydrogel. Endoplasmic reticulum (ER) stress-related apoptosis was analyzed to explore the possible mechanisms in IUA recovery. E\textsubscript{2}-HP hydrogel showed a prolonged release of E\textsubscript{2} at the targeting region and more effective endometrium regeneration in IUA rats. Significant improvements in both gland numbers and fibrosis area were observed in the E\textsubscript{2}-HP hydrogel group. We also demonstrated that E\textsubscript{2}-HP hydrogel in the recovery of IUA was closely related to the suppression of ER stress signals via the activation of downstream signals, PI3K/Akt and ERK1/2. HP hydrogel might be an effective approach to deliver E\textsubscript{2} into the injured endometrium. Therapeutic strategies targeting ER stress using E\textsubscript{2}-HP hydrogel might be a promising solution for the treatment of women with intrauterine adhesions.

Keywords: intrauterine adhesions, 17β-estradiol, heparin-poloxamer hydrogel, endometrium regeneration, endoplasmic reticulum stress

Introduction

Intrauterine adhesions (IUA), also known as Asherman’s Syndrome, is characterized by fibrosis or adhesions within the uterine cavity as a result of damage or infection to the basal layer of the endometrium.\textsuperscript{1} IUA increases the risk of menstrual abnormalities, secondary infertility, recurrent miscarriage, and pregnancy complications.\textsuperscript{2} Common treatments include hysteroscopic adhesiolysis and administration of hormonal drugs to promote the regeneration of the endometrial tissue. However, readhesion and side effects frequently occur.\textsuperscript{3} Although hysteroscopic lysis of adhesions is the most...
effective method to re-establish the anatomy of the uterine cavity and restore endometrial function, the procedure itself contributes to readhesions because it may damage the epithelial cells postoperatively. Therefore, it is imperative to find a treatment that targets the cellular and molecular mechanisms underlying the pathophysiology of IUA.

The endoplasmic reticulum (ER) is an essential intracellular organelle in which proteins are synthesized and folded. Many events such as exposure to free radicals and consumption of ER Ca\(^{2+}\) stores can lead to an unfolded protein response (UPR) and trigger ER stress.\(^5,6\) Although the original activation of the UPR can protect the cell against these adverse situations, sustained or excessive UPR is harmful and contributes to cell apoptosis. Accumulation of unfolded proteins within the ER lumen can simultaneously lead to the overexpression of glucose-regulated protein 78 (GRP78/Bip) and C/EBP homologous protein (CHOP), and activate the caspase-12, a crucial protein related to cell apoptosis induced by ER stress.\(^8\) Recent studies have revealed that ER stress-induced apoptosis plays an important role in the pathogenesis and development of many diseases.\(^9\) Bitulco et al indicated that the activation of UPR and the alteration of GRP78 expression were involved in endometrial cancer development and progression.\(^10\) However, there are few studies on the role of UPR and ER stress in the treatment of IUA.

17β-estradiol (E\(_2\)) is an important steroid hormone. It has been demonstrated that E\(_2\) can effectively promote endometrial regeneration and form new capillaries after menstruation.\(^11\) Estrogen therapy is commonly used as an ancillary treatment after adhesiolysis since it accelerates the regeneration of the endometrial layer and therefore prevents recurrent adhesions.\(^12\) Evidence from many studies indicates that the application of estrogen therapy in patients with IUA results in satisfactory outcomes.\(^5\) However, 17β-estradiol, by either oral delivery or systemic administration, imposes restrictions on its clinical use because of its limited half-life period in vivo, poor solubility in aqueous solutions, and low concentrations at the injured endometrium. Therefore, it may be important to enhance local concentrations to improve the efficacy of 17β-estradiol.

Heparin-poloxamer (HP), co-polymers consisting of polypropylene oxide (PPO) and polyethylene oxide (PEO) units, have been commonly used as sustained-release drug delivery systems. In response to the alteration of concentration and temperature, the PEO hydrophilic units remain hydrated, while the PPO hydrophobic units are dehydrated and they aggregate, forming the micellar core and corona, respectively. Then, these micelles are self-assembled in ordered cubic or hexagonal phases, producing the thermosensitive hydrogels. They are nontoxic and biodegradable, and with proper formulation, they can increase the solubility, stability, and bioavailability of the incorporated drugs.\(^13\) In general, HP hydrogel has been widely used for loading and delivering molecules to treat different diseases.\(^13,14\) Recently, Wu et al developed and characterized an HP hydrogel containing acidic fibroblast growth factor (aFGF) for wound treatments and showed a clear therapeutic effect.\(^15\) In addition, HP hydrogel loading nerve growth factor (NGF) enhanced the neuron regeneration in spinal cord injury.\(^16\) Therefore, we consider that HP hydrogel may be a useful drug delivery system for 17β-estradiol in IUA.

In this research, we attempted to prepare and characterize a novel HP thermosensitive hydrogel loading 17β-estradiol (E\(_2\)-HP hydrogel) with the purpose of developing a sustained releasing delivery system of 17β-estradiol and further increased its biological effect in vivo. Our results suggested that E\(_2\)-HP hydrogel had more biological effects than E\(_2\) solution only, which showed that the E\(_2\)-HP hydrogel had a therapeutic potential to treat IUA.

Materials and methods
Reagents and antibodies
All reagents used in this study were commercially available. 17β-estradiol was purchased from Sigma-Aldrich (St Louis, MO, USA). Dulbecco’s Modified Eagle’s Medium/F-12 (DMEM/F-12) and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA, USA). Poloxamer 407-grafted heparin copolymer was synthesized by our laboratory, as previously reported.\(^17\) GRP78, CHOP, anti-Akt, phosphorylated-Akt (Ser473), anti-ERK, and phosphorylated-ERK antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). VEGF, Ki67, TGF-β, and caspase-12 were ordered from Abcam (Abcam, CB, UK). PI3K/Akt inhibitor LY294002, ERK1/2 inhibitor PD98059, and all other reagents were purchased from the Beyotime Institute of Biotechnology (Shanghai, China), unless otherwise specified.

Preparation of E\(_2\)-HP hydrogel
HP hydrogel was prepared according to the 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS) method.\(^18\) E\(_2\)-HP hydrogel, including different amounts of HP hydrogel and 17β-estradiol, was prepared using the cold method. Briefly, lyophilized HP powder was added to purified water under moderate magnetic agitation and in ice bath. The solution was kept at 4°C for a period of 24 h to ensure the complete dissolution of the polymer. Then, 17β-estradiol was added to a microtube containing 500 mL of alcohol and solubilized using vortex. The solution was immediately added to the HP solution under vigorous
magnetic agitation and in an ice bath. The alcohol was completely evaporated under vacuum using a conventional rotary evaporation method (Buchi, Flawil, Switzerland). The final weight of the formulation was set up with purified water to obtain the final concentration of 18% w/w (weight/weight) of HP and 0.2 mg of 17β-estradiol, per gram of formulation.

**Micromorphology of E₂-HP hydrogel**

The micromorphology of the dehydrated HP hydrogel and E₂-HP hydrogel was observed by a scanning electron microscope (SEM; Hitachi, H-7500, Japan). The samples were placed on a copper sheet and dipped into liquid nitrogen immediately. After this process, the hydrogels were dried by a vacuum freeze dryer for 24 h. The dehydrated specimens were then cross-sectioned and sputter-coated with gold. Their surface morphology was observed using an SEM.20

**In vitro release of drug**

E₂ solution and E₂-HP hydrogel were prepared as previously described. In vitro release of E₂ was prepared according to the literature, with some modifications.20 In brief, 1 mL E₂ solution and 1 mL E₂-HP hydrogel were placed in a tube. Then, a release medium was added to the samples, and the tubes were placed in a shaking incubator at 37°C with continuous shaking at 100 rpm. At each time point (0, 0.5, 1, 2, 4, 8, 12, 24, 48, and 72 h), E₂ was sampled through the supernatant and then replaced with an equal volume of fresh medium. The released E₂ was analyzed by high-performance liquid chromatography at 280 nm. The amount of released E₂ was normalized through the former and final concentrations. The release experiments were performed in triplicate.

**In vivo intrauterine retention and sustained release of drug**

To investigate in vivo intrauterine retention and sustained release of E₂-HP hydrogel, 18% poloxamer hydrogel loaded with 0.2 mg/mL 17β-estradiol-BSA-FITC was prepared and injected into the right cavity of uteri, whereas 17β-estradiol-BSA-FITC solution served as a control group. After injection, rats were sacrificed and the uteri were collected at 1, 2, 8, 24, 48 h followed by washing with saline. Fluorescent images of intact uteri were taken using an In Vivo IVIS spectrum imaging system (a wavelength of 500 nm and at an excitation wavelength of 465 nm).

**Isolation and culture of primary mouse endometrial epithelial cells**

The procedure for the isolation of primary mouse endometrial epithelial cells (EECs) was performed according to the literature, but with some modifications.21 In brief, the uteri were cut into small pieces and digested with 0.1% collagenase and 0.25% trypsin-ethylenediamine-tetra-acetic acid. After digesting for 60 min under slight shaking, the digestive reaction was stopped by adding the complete medium into solution. Then, the EECs were isolated by the following protocol: the digested cells suspension was centrifuged for 3 min at 500 rpm. After this, DMEM/F-12 culture medium was used to wash the precipitate. Subsequently, trypsin-ethylenediamine-tetra-acetic acid (0.25%) was added to the precipitates and incubated in CO₂ at 37°C for 10 min. The suspension was centrifuged again at 800 rpm for 5 min and a complete culture medium was used to resuspend precipitates. The primary EECs were cultured in DMEM/F-12 supplemented with 10% FBS and 1% penicillin and streptomycin in a humidified incubator (Thermo, San Diego, CA, USA) under 5% CO₂ at 37°C.

**Cell viability assay**

EECs were seeded on 96-well plates for 24 h and treated with different doses of hydrogen peroxide (H₂O₂) solution. From the cells’ survival state, 400 μmol/L H₂O₂ was selected for the subsequent experiments. For determining the protection effect of E₂-HP hydrogel on EECs, various doses of E₂ solution and E₂-HP hydrogel were added after the addition of H₂O₂ for different times. Then, 10 μL of cell counting kit (CCK)-8 was added into each well. Four hours later, the 450 nm absorption was observed by a microplate reader.

**Animal models and experimental groups**

This study was approved by the Animal Care and Use Committee of Wenzhou Medical University. All animal-handling procedures were performed according to the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health. Female Sprague-Dawley rats (230–250 g) at the age of 8 weeks were purchased from the Animal Center of Chinese Academy of Sciences, Shanghai, China. In this study, the surgical models were created at diestrus stage when the uterine lining began to appear. All the animals were anesthetized by an intraperitoneal injection of 1% pentobarbital sodium (0.5 mL/kg). After this, a vertical incision was made in the abdominal midline and the uteri were identified. A horizontal incision (0.2 cm) was made on the uterus 0.5 cm above its bifurcation. The mechanical injury entailed the scraping of endometrium using a mini-endometrial curette. Saline, HP hydrogel, E₂ solution, and E₂-HP hydrogel were injected into bilateral uterine lumens at a dosage of 30 μL through the micro syringe immediately after operation. In the sham operation group, animals received...
the same surgical procedures without any treatment for the uteri (Figure 1). According to our preliminary experiments, rats were sacrificed and uteri were harvested at day 14 post surgery.

**Ultrasonography measurement**

Fourteen days after surgery, three rats of each group were anesthetized by an intraperitoneal injection of 1% pentobarbital sodium (0.5 mL/kg). The rats were then placed on a cork platform in supine position with preparation of the abdominal skin. Ultrasonography measurements were performed by a trained sonographer. Among all experiments, the standard setting of each parameter was kept consistent.

**Histological analysis**

For histological preparation, the uteri were fixed with 4% paraformaldehyde, embedded in paraffin and sliced into 5 μm thickness sections. The transverse sections were stained with hematoxylin–eosin and Masson stains (Beyotime Institute of Biotechnology, Shanghai, China) by conventional methods. The number of glands on each hematoxylin–eosin stained section was counted in each of the five randomly selected fields under high power, and the mean was calculated. Five high-power fields of each Masson-stained section were randomly chosen to quantify the degree of endometrial fibrosis.

**Immunohistochemical staining**

For immunohistochemistry, the transverse paraffin sections were deparaffinized, rehydrated, and then incubated in 3% H₂O₂ for 15 min at room temperature. After this, the sections were heated to recover antigen. Then, the samples were blocked using 5% bovine serum albumin (BSA) (Beyotime) for 30 min at 37°C. Subsequently, the sections were incubated with the following primary antibodies: Ki67 (1:100), VEGF (1:100), TGF-β (1:100), CHOP (1:200), GRP78 (1:200), and caspase-12 (1:400) at 4°C overnight. Then, the sections were incubated with tagged secondary antibody with either goat antimouse or goat antirabbit for 2 h at 37°C. The reaction was stopped with 3,3-diaminobenzidine. The results were imaged using a Nikon ECLPSE 80i (Nikon, Tokyo, Japan). The optical densities and positive staining cell numbers were quantified at five randomly selected fields per section.

**Western blot analysis**

Total proteins from injured uterine tissues and primary mouse EECs were purified using protein extraction reagents according to the instructions. The equivalent of 20 μg of protein was separated by 12% gel and transferred onto PVDF membrane (Bio-Rad, Hercules, CA, USA). After blocking with 5% fat-free milk for 2 h, the membranes were incubated with the relevant protein antibodies overnight. TBST were used to wash the membranes three times. After this process, the membranes were treated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. The signals were visualized with the ChemiDicTMXRS + Imaging System (Bio-Rad Laboratories), and the band densities were quantified with Multi Gauge Software of Science Lab 2006 (FUJIFILM Corporation, Tokyo, Japan).

**Statistical analysis**

Results were expressed as the mean ± SD for each group. Student’s t-tests were performed to determine the significance of
for which almost all drug (~80%) was immediately released to dissolve the medium at 2 h in the release study. However, E₂-HP hydrogel demonstrated a sustained release of E₂ for over 72 h. At the end of the experiment, about 95% E₂ was released from the hydrogel. These results further suggested that the structure of the gel functioned as a resistant barrier to the release of E₂ at body temperature. Prolonged release of E₂ at a constant rate from the hydrogel might make it a useful biomaterial for the long-term treatment of IUAI.

In vivo intrauterine retention and release of estradiol

As shown in Figure 4, 17β-estradiol-BSA-FITC revealed sustained release from the hydrogel after infusion into the right uterus. Over time, the fluorescence intensity in the uterine cavity gradually became weaker. At 48 h, the fluorescence signals in the uterus completely disappeared. Compared with the HP hydrogel, the fluorescence intensity of 17β-estradiol-BSA-FITC solution decreased rapidly and almost disappeared at 2 h. These results proved the controlled-release behavior of HP hydrogel for the loaded micromolecule, which provided the foundation for the application of E₂-HP hydrogel in IUAI treatment.

E₂-HP hydrogel promotes EEC survival rate in vitro

To investigate an appropriate concentration of H₂O₂ and E₂ in EECs, we conducted dose–response experiments. We found...
that incubation with H$_2$O$_2$ led to dose-dependent cell death after a 4-hour exposure. From the result, 400 $\mu$mol/L H$_2$O$_2$ was chosen to establish the cell model. In addition, the cell viability of EECs after treatment with E$_2$ solution increased significantly at the concentrations of 100 nmol/L in all tested incubation times (Figure 5A). On the basis of this result, 100 nmol/L E$_2$ solution was selected for subsequent experiments. As shown in Figure 5B, remarkable proliferation of EECs was noted after treatment with E$_2$ solution or E$_2$-HP hydrogel for 24, 48, and 72 h. E$_2$-HP hydrogel group was obviously higher than that in E$_2$ solution. No significant difference was found between control and HP hydrogel groups. These results further suggested that the occurrence of a sustained-release of E$_2$ from the E$_2$-HP hydrogel might be profitable for cell proliferation.

**Ultrasonography measurement of the injured uterus in vivo**

In this study, we assessed the treatment outcomes of IUA using two-dimensional ultrasound. In the sham operation group, the echo of endometrium was uniform with a clearly visible endometrial line in the middle. However, an uneven internal echo of the uterine cavity was seen in IUA and HP hydrogel groups, and the endometrial line was discontinuous in these groups. After treatment with E$_2$ solution, this line was slightly restored in the damaged uterus. Treating with E$_2$-HP hydrogel showed a better repairing effect than E$_2$ solution group (Figure 6). These results convincingly demonstrated that the administration of E$_2$-HP hydrogel improved the regeneration of endometrium on IUA.

**E$_2$-HP hydrogel increases the number of glands and decreases the fibrosis area in IUA model**

Hematoxylin–eosin staining results of the uteri samples from the different experimental groups after 14 days were shown in Figure 7A. In the sham operation group, the endometrial surface was lined with simple high columnar epithelial cells. Round or oval glands were primarily found in the submucosa and basal layer, and there were large openings
at the endometrial surface (Figure 7A). Fourteen days after endometrial scraping, the surface in the IUA group was almost covered by flat and low columnar epithelial cells, and adhesion of uterine cavity could be detected in some animals. Meanwhile, a few glands were visible beneath the epithelial layer (Figure 7A). No difference was found in the number of glands between IUA group and HP hydrogel group. Compared with the IUA group, the number of glands on day 14 after intervention slightly increased in the E₂ solution group. The E₂-HP hydrogel group showed remarkably higher numbers of glands, similar to the sham operation group and better than the E₂ solution group (Figure 7). These results indicated that synergistic interactions between HP hydrogel and E₂ offered a more efficient repair effect at the endometrial injury site.

Figure 6 Ultrasonography measurement of the injured uterus in different groups at 14 days after IUa.
Notes: The red dotted lines indicate the uterine cavity. The red arrowheads indicate the endometrial line; n=5.
Abbreviations: IUa, Intrauterine adhesions; HP, heparin-poloxamer.

Figure 5 Cell viability of various groups in vitro.
Notes: (A) Endometrial epithelial cells (EECs) were pretreated with H₂O₂ for 4 h and were treated with different concentrations of E₂ solution for 8 h, 12 h, and 24 h. Then, the cell viability was assessed by the CCK-8 assay. *P<0.05 versus H₂O₂ group. (B) EECs were pretreated with H₂O₂ for 4 h and were treated with different treatments for 24, 48, and 72 h. Then, the cell viability was assessed by the CCK-8 assay. *P<0.05 and **P<0.01 versus H₂O₂ group. Data are presented as mean ± standard deviation; n=3.
Abbreviations: CCK-8, cell counting kit-8; EECs, endometrial epithelial cells.
almost no collagen deposition in the endometrial stroma. In contrast, the ratio of the area with endometrial fibrosis in the IUA group was significantly increased compared with the sham operation group. There was no significant difference in the extent of endometrial fibrosis between the IUA and HP hydrogel groups. Treatment with E₂ solution alone did not obviously reduce the endometrial fibrosis in IUA rats. Only when the IUA rats were subjected to the combination treatment of E₂-HP hydrogel, the degree of endometrial fibrosis was moderately but significantly decreased. As shown in Figure 7, the change in endometrial fibrosis was inversely related to the number of glands in the rats of each group.

E₂-HP hydrogel promotes cell proliferation and vascularization in the injured endometrium

To evaluate the effect of E₂-HP hydrogel treatment on the regeneration of endometrium, we assessed the expression of Ki67, a nuclear antigen for cell proliferation at all stages, to assess whether E₂-HP hydrogel could promote the proliferation of the endometrial cell. As shown in Figure 8A, the numbers of proliferative cells were weakly detected or were absent in the IUA group. No significant difference in Ki67 expression was observed between IUA and HP hydrogel groups. Compared with the IUA group, we demonstrated a statistically significant increase of Ki67 at the epithelial compartment.
in the $E_2$-HP hydrogel group. The $E_2$ solution alone also improved the regeneration of IUA, but $E_2$-HP hydrogel led to a more remarkable improvement of injury. These results buttressed the fact that the administration of $E_2$-HP hydrogel improved the proliferation of endometrium on IUA.

Immunohistochemical staining demonstrated that TGF-$\beta$ was mainly expressed both in the nucleus and in the cytoplasm of epithelial and stromal cells. As shown in Figure 8A, the expression of TGF-$\beta$ in the endometrium of IUA was distinctly increased compared with that in the sham operation group. Moreover, TGF-$\beta$ showed strong expression in the endometrial tissue of HP hydrogel group. The quantity of TGF-$\beta$ in the $E_2$ solution group was mildly lower than that of the IUA group. Most strikingly, we observed that the level of TGF-$\beta$ significantly declined in the $E_2$-HP hydrogel group, similar to that in the sham operation group (Figure 8C). Collectively, these results indicated that TGF-$\beta$ may play a crucial role in IUA formation. And delivering of $E_2$ with the thermosensitive heparin poloxamer hydrogel was effective in inhibiting the expression of TGF-$\beta$.

Vascular endothelial growth factor (VEGF) is a well-known angiogenic factor, which is essential for neovascularization. Evidence shows that VEGF also has additional functions such as antiapoptosis and vascular remodeling. To explore the possible involvement of VEGF in the repair of endometrium, we estimated the quantity of VEGF by performing immunohistochemical staining (Figure 8A and D). The results showed that VEGF was significantly decreased in IUA and HP hydrogel groups compared with that in the sham operation group. After the administration of $E_2$ solution,
the level of VEGF was slightly upregulated in the damaged endometrium, whereas treating with E₂-HP hydrogel showed more evident expression of VEGF than the E₂ solution group. To further validate the expression of VEGF in endometrium, a Western blot assay was performed, with a representative blot exhibited in Figure 10A. The relative expression of VEGF proteins was counted through normalization to GAPDH, as summarized in Figure 10C. Consistent with the results of immunohistochemical staining, changes in VEGF expression were observed across experimental groups. Taken together, these findings indicated that HP hydrogel enhanced the therapeutic effect of E₂ on angiopoiesis after IUA.

**E₂-HP hydrogel inhibits ER stress signaling pathway in IUA model**

To further explore whether the mechanism of E₂-HP hydrogel is related to the alteration of ER stress, the expression of the ER stress-induced apoptosis signal pathway was evaluated. As shown in Figure 9, ER stress-related apoptosis protein (GRP78, caspase-12 and CHOP) positive cells were obviously increased in the IUA group compared with those in the sham operation group. No significant difference in apoptosis protein expression was observed between IUA and HP hydrogel groups. Meanwhile, positive cells reduced in the E₂ solution and E₂-HP hydrogel groups. It was evident that E₂-HP hydrogel resulted in less positive cells than E₂ solution alone. Furthermore, the expression of GRP78, CHOP, and cleaved caspase-12 were also analyzed by Western blot analysis (Figure 10A and B). Similar to the results of immunohistochemical staining, the levels of the ER stress-related protein were significantly elevated in the injured region of the endometrium in IUA group when compared with the sham operation group. Treatment with E₂ solution suppressed the activation of ER stress-induced proteins, and these protein

---

**Figure 9** E₂-HP hydrogel inhibits ER stress-induced apoptosis in IUA rats.

**Notes:** (A) Immunohistochemistry for GRP78, caspase-12, and CHOP (400x) on the 14th day after different treatments with IUA; (B) Quantitative analysis of GRP78-positive cells of the immunohistochemistry results; (C) Quantitative analysis of caspase-12-positive cells of the immunohistochemistry results; (D) Quantitative analysis of CHOP-positive cells of the immunohistochemistry results. Data are presented as mean ± standard deviation; n=5; *P<0.05 and ***P<0.001.

**Abbreviations:** CHOP, C/EBP homologous protein; ER, endoplasmic reticulum; GRP78, glucose-regulated protein; IUA, Intrauterine adhesions; HP, heparin-poloxamer.
levels in $E_2$-HP hydrogel-treated rats were relatively lower than those in the $E_2$ solution group.

The protective role of $E_2$-HP hydrogel is related to the activation of downstream signal pathways PI3K/Akt and ERK1/2

PI3K/Akt and ERK1/2 pathways are two main downstream signals activated by $E_2$. These signal pathways are strongly linked to cell survival, migration, and differentiation. To further explore the underlying mechanisms behind the effect of $E_2$-HP hydrogel in the recovery of IUa, the activation of PI3K/Akt and ERK1/2 downstream signals was evaluated. Our Western blot analysis revealed that the levels of phosphorylation of Akt and ERK1/2 decreased after IUa intervention. However, the reductions of $p$-Akt and $p$-ERK1/2 were reversed after the administration of $E_2$ solution or $E_2$-HP hydrogel. The $E_2$-HP hydrogel group showed more obvious upregulation of these proteins than did the $E_2$ solution group (Figure 10A and C). Taken together, these results suggested that the protective role of $E_2$-HP hydrogel in endometrial impairment was linked to the inhibition of ER stress through the activation of the PI3K/Akt and ERK1/2 signaling pathways.

The activation of downstream signals is vital for the protective effect of $E_2$-HP hydrogel

To further explore the molecular mechanism of $E_2$-HP, the PI3K inhibitor LY294002 and the ERK1/2 inhibitor PD98,059 were added to the media. In our previous study, none of these inhibitors showed any effect on cell death. As shown in Figure 10A, $H_2O_2$-induced activation of GPR78, cleaved-caspase-12, and CHOP was decreased after treatment with $E_2$-HP hydrogel. After the combined exposure to Akt/ERK1/2 inhibitors, the inhibitory effect of $E_2$-HP hydrogel on the expression of GPR78, cleaved caspase-12, and CHOP...
was reversed (Figure 11A and B). Consistent with this, our Western blot results demonstrated that E2-HP hydrogel triggered the activation of p-Akt, and p-ERK1/2 was also attenuated by Akt/ERK1/2 inhibitors (Figure 11A and C). All of these results suggested that the protective effect of E2-HP hydrogel was regulated by both the PI3K/Akt and ERK1/2 signaling pathways.

**Discussion**

Intrauterine adhesions usually occur as a result of infectious or mechanical injury to the endometrium, leading to partial or complete adhesions of the wall of the uterine cavity and/or the cervical canal. Ever since Heinrich Fritsch first described this condition in a patient with secondary amenorrhea, the incidence of IUA has seen an increase in some parts of the world.21 In China, it has been reported that about 7% of cases of secondary amenorrhea and 40% of cases of infertility are caused by IUA, which remains a severe threat to reproductive women.2 Over the decades, many experimental studies have focused on the regeneration of endometrium and on the prevention of scar reformation. One of the traditional therapeutic approaches for intrauterine adhesions is placing an IUD in the uterine cavity. However, because of their poor biocompatibility, IUDs can impede normal endometrial regeneration and easily cause infection.21,22 At present, some possible treatments of IUA include direct delivery of specific growth factors or stem cells into the uterus. A recent study by Zhao et al showed a positive effect of bone marrow mesenchymal stem cells treatment on a rat model with thin endometrium.23 Moreover, a collagen scaffold loaded with...
collagen-binding human basic fibroblast growth factor was employed to facilitate the recovery of rat uterine horns, and this delivery system accelerated the regenerative abilities of uterus and attained a better pregnancy outcome.\textsuperscript{24} But all of these treatments available to moderate and severe IUA are limited and inefficient. Thus, more studies and new therapies are urgently needed to better understand the pathogenesis of this disease.

17β-estradiol is an essential member of the steroid hormones. It is responsible for uterine endometrial regeneration through stimulating the proliferation and differentiation of stem cells after menstruation. In clinical practice, post-operative treatment with estrogen therapy is considered as the most effective method to re-establish a normal uterine cavity and restore endometrium function in IUA patients.\textsuperscript{25} A recent systematic review provided sufficient evidence that the administration of estrogen could reduce reformation of IUA by promoting endometrial repair and covering the denuded endometrial layer.\textsuperscript{2} Moreover, many studies revealed that using estrogen therapy alone as ancillary treatment was associated with satisfactory outcomes. The restoration of menstrual flow and pregnancy rate was substantially increased when compared with the group that did not receive any hormone therapy.\textsuperscript{26,27} Although these are promising results, there are still many limitations that need to be addressed. First, recurrence of uterine cavity adhesion after estrogen therapy is frequently observed, especially in severe IUA patients.\textsuperscript{28} Second, the 17β-estradiol at high systemic levels may increase the risk for thrombosis and malignancy.\textsuperscript{29} Third, by either oral delivery or systemic administration, 17β-estradiol always shows a low concentration at the injured uterus, which may reduce its therapeutic effect.

Based on these situations, in situ administration of 17β-estradiol may be a suitable delivery choice. However, it is hard to retain 17β-estradiol solution at the injury endometrium through simple injections or infusions because of its rapid diffusion into extracellular fluids.\textsuperscript{30} Therefore, the aim of this study is to develop a new sustained releasing system intended for the in situ administration of 17β-estradiol in the uterus and characterized by extended local exposure, fewer side effects, and lower production cost.

HP hydrogel, which has good biocompatibility and a controlled phase alteration temperature, is appropriate for in situ administration.\textsuperscript{15,30} In a typical experiment, HP hydrogel exhibited a liquid state in low temperature. After it was locally administered in vivo, a three-dimensional network structure was formed which sustained the drug releasing from the HP hydrogel. In our previous study, HP hydrogel loaded with growth factors was synthesized and it showed remarkable therapeutic outcomes in wound healing.\textsuperscript{16} We also found that HP hydrogel effectively increased the delivery of NGF via the blood-spinal cord barrier and showed a significant neuroprotective improvement in rats with spinal cord injury.\textsuperscript{14} Therefore, a similar delivery system was applied in this study. We provided the first evidence that 17β-estradiol-loaded HP hydrogel effectively enhanced endometrial regeneration and the IUA recovery compared with 17β-estradiol only in cellular and animal models.

In this work, E\textsubscript{2}-HP hydrogel showed a prolonged release of E\textsubscript{2} at the targeting region and more effective endometrium regeneration at 14 days after surgery than did all the other groups. The number of glands was significantly increased in the E\textsubscript{2}-HP hydrogel group, similar to that in the sham operation group. In addition, the ratio of fibrotic tissue area was markedly decreased after treatment with E\textsubscript{2}-HP hydrogel. Moreover, there was an apparent increase in the number of proliferative cells in the E\textsubscript{2}-HP hydrogel group than in the control group. Furthermore, in this study, the in situ administration of E\textsubscript{2}-HP hydrogel increased the expression of angiogenesis factor, VEGF, in the damaged area, suggesting that angiogenesis might improve in the treated area. Thus, the E\textsubscript{2}-HP hydrogel-induced regeneration of endometrium might result from increased vascularity and therefore increased access to nutrients, oxygen, and hormones in the damaged area.

In our study, we not only showed the effectiveness of E\textsubscript{2}-HP hydrogel on IUA, but also explored the possible mechanisms underlying the therapeutic effects of E\textsubscript{2}-HP hydrogel. There is increasing evidence to suggest that ER stress signal plays an important role in promoting cell death in many diseases. A recent study demonstrated that ER stress-induced apoptosis was related to the response of spinal cord injury and that the expression of apoptosis-related proteins, including GRP78, caspase-12, and CHOP protein, was obviously increased after injury.\textsuperscript{31} A similar phenomenon was observed in myocardial ischemia/reperfusion injury.\textsuperscript{32} However, the role of ER stress signaling in IUA has never been reported. In the current study, we first showed that ER stress-induced apoptosis was involved in the progression of IUA. The levels of related proteins increased evidently in vivo, and was confirmed in EECs’ injury models induced by H\textsubscript{2}O\textsubscript{2}. On the basis of these studies, suppressing this process and protecting IUA-associated apoptosis may be a novel therapeutic strategy for IUA.

Moreover, Haas et al had indicated that dextrose-induced ER stress in human umbilical vein endothelial cells was
reversed by E2.33 Another study published by Guo et al revealed that 17β-E2 protected MC3T3-E1 cells against ER stress-induced apoptosis by accelerating Ras-ERK1/2-TFII-I signaling pathway-dependent GRP78 induction.34 In this study, we revealed that exogenous E2-HP hydrogel treatment after injury reduced the expressions of ER stress-induced apoptosis proteins and promoted the regeneration of endometrium. In addition, the repair activity of E2-HP hydrogel was also revealed in the H2O2-induced EECs’ injury model. Taken together, these results indicated that ER stress-induced apoptosis could be inhibited by exogenous E2-HP hydrogel administration.

As the main downstream signals activated by E2, the PI3K/Akt and ERK1/2 pathways play an important role in several cellular processes, including proliferation, survival, and motility.35,36 A recent study demonstrated that estrogen in low dose was closely related to rapid increase in Akt and ERK phosphorylation in rat hippocampus, thus promoting cell survival of the neurons.37 Moreover, Zhou et al had reported that 17β-estradiol-induced keratinocyte proliferation might be mediated by the Akt/Erk signaling pathway.38 In addition, a previous study had shown that E2 was involved in the migration of endometrial stromal cells by activating the same signaling routes.39 Besides these findings, a previous in vitro study illustrated that low concentrations of E2 were able to counteract endoplasmic reticulum stress-induced apoptosis by Akt pathway in SGC7901 cells.40 Therefore, we hypothesized that E2 accelerated the regeneration of injured endometrium by suppressing ER stress-induced apoptosis via the ERK/Akt signaling pathway. In our study, the levels of phosphorylation Akt and phosphorylation ERK significantly declined both in vivo and in vitro. Moreover, the reductions of p-Akt and p-ERK1/2 were reversed after treatment with E2-HP hydrogel. To further certify that these two pathways were vital for the protective effect of E2-HP hydrogel, the PI3K/Akt inhibitor LY294002 and the ERK1/2 inhibitor PD98059 were used to treat EEC cells. Results revealed that apoptosis induced by H2O2 was inhibited by treating with E2-HP hydrogel and further vanished by this combination of inhibitors. Taken together, we speculated that the role of E2-HP hydrogel in IUA recovery was involved in the activation of both the PI3K/Akt and ERK1/2 signals.

In conclusion, the current study demonstrated that the administration of E2-HP hydrogel was effective in IUA caused by endometrial damage in the rat model. This was related to the inhibiting of ER stress-induced apoptosis and augmenting of the angiogenesis factor VEGF. Furthermore, activation of the two downstream signaling pathways PI3K/Akt and ERK1/2 was indispensable for the effect of E2-HP hydrogel in endometrial cell regeneration both in vivo and in vitro. However, the complex mechanism of endometrium regeneration in the IUA model needs to be further investigated before an in situ administration technique can be brought from bench to bedside. Since the goal of this research is to reveal safety and short-term efficacy of this drug delivery system, more studies for the long term effect of single versus repeated treatments using this approach are needed. Moreover, alternate approaches, such as to deliver E2 combined with growth factors to the injury, may also be promising strategies.

Acknowledgments

This research was supported by the Science and Technology Project of Zhejiang Province (Grant No 2016C37132), National Natural Science Foundation of China (Grant No 81571392 and 81603036), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (Ying-Zheng Zhao), 151 Talent Project of Zhejiang Province and 551 Talent Project of Wenzhou (Ying-Zheng Zhao), 551 Talent Project of Wenzhou (Xue-Qing Wu), Zhejiang Provincial Foundation for Health Department (Grant No 2015ZDA023 and 2016KYA136), key support of high-level talent innovation and technology project of Wenzhou (Ying-Zheng Zhao), medicine grant from the Wenzhou Bureau of Science and Technology (Grant No Y2014730 and Y20140726), and the Public Welfare Scientific and Technology Project of Wenzhou (No Y20140743).

Disclosure

The authors report no conflicts of interest in this work.

References


